Last year the FDA approved WEGOVYTM injection for weight loss . This has been a game changer for the majority of patients and we are seeing excellent results with the use of Wegovy™. Ozempic is the same medication as Wegovy™ and has been used for the treatment of type 2 diabetes mellitus for many years.
Semaglutide was developed in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide as a once-weekly diabetes therapy. It was given the brand name Ozempic. Clinical trials were started on 6 January 2016, and completed on 19 May 2017. It was FDA approved in December 2017 for the treatment of type 2 Diabetes. It was observed that patients were losing a significant amount of weight on this drug.A new trial was done in patients without dm2 to observe weight loss. The results showed that patients on semaglutide lost an average of 20 % of their weight.
Wegovy™ (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist which is used along with diet and exercise for chronic weight management in adult patients who are overweight (BMI ≥27 kg/m2) or obese (BMI ≥30 kg/m2).
Wegovy™ works by decreasing food intake by activating GLP-1 receptors. These receptors are present in many areas of the brain and are involved in appetite regulation. It increases the production of insulin, a hormone that lowers the blood sugar level. It appears to increase the growth of β cells in the pancreas, which are the sites of insulin production.
It inhibits the production of glucagon, which is a hormone that increases blood sugar. It slows down digestion in the stomach resulting in a feeling of fullness.
Wegovy™ is administered by subcutaneous injection once weekly, with or without meals. It can given anywhere in the belly.
Who cannot use Wegovy™ injection for weight loss? Anyone with a history of medullary thyroid cancer or pancreatitis should not use Wegovy™.
The most common side effects of Wegovy™ injection include nausea, diarrhea, vomiting, constipation, stomach pain, headache,fatigue, upset stomach, dizziness, feeling bloated, belching, gas, stomach flu and heartburn.
The doctor can prescribe you nausea medication. Your body generally adapts and as you continue to use the medicine, these side effects will decrease.
Inflammation of your pancreas (pancreatitis). if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting this may mean you have pancreatitis gallbladder problems. Wegovy™ may cause gallbladder problems, including gallstones.
Increased risk of low blood sugar (hypoglycemia) in patients with type 2 diabetes, especially those who also take medicines for type 2 diabetes such as sulfonylureas or insulin.
Remember, this is not a complete list of side effects. This is just basic information for you to get started. Please talk to your doctor for further information.
In May 2022, the FDA approved tirzepatide (Mounjaro) for the treatment of Type 2 diabetes in adults. Tirzepatide’s FDA approval marks the first in a new class of diabetes medications: a dual GIP/GLP-1 receptor agonist. It also causes significant weight loss but is currently not yet approved for weight loss.
All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice. Statements made on this website have not been evaluated by the Food and Drug Administration. The information contained herein is not intended to diagnose, treat, cure or prevent any disease. *Results may vary